NCT00511836View on ClinicalTrials.gov

ALK21-018: Effects of Medisorb® Naltrexone (VIVITROL®) on Alcohol Craving in Treatment-seeking, Alcohol-dependent Adults

PHASE4CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

June 30, 2009

Study Completion Date

October 31, 2009

Conditions
Alcohol Dependence
Interventions
DRUG

VIVITROL 380 mg

Administered via intramuscular (IM) injection once during the double-blind phase and for 2 additional injections, 4 weeks apart, during the optional open-label extension.

DRUG

Placebo

Placebo matching VIVITROL 380 mg was administered by IM injection once during the double-blind phase, only.

Trial Locations (1)

02478

McLean Hospital, Belmont

Sponsors

Lead Sponsor

Alkermes, Inc.
All Listed Sponsors
lead

Alkermes, Inc.

INDUSTRY

NCT00511836 - ALK21-018: Effects of Medisorb® Naltrexone (VIVITROL®) on Alcohol Craving in Treatment-seeking, Alcohol-dependent Adults | Biotech Hunter | Biotech Hunter